You are here: Industry Insights > Sutro Biopharma

News List

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer drugs
August 25, 2021
Sutro Biopharma today announced that the U.S.FDA has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC).
Sutro Biopharma Announces Interim Data on STRO-002 Study for Ovarian Cancer americanpharmaceuticalreview
December 24, 2020
Sutro Biopharma has provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer.
Sutro Biopharma Achieves Merck KGaA Clinical Supply Milestone contractpharma
August 26, 2020
Delivers GMP clinical trial supply to Merck KGaA for Phase 1 trial of M1231, a bispecific ADC for the treatment of solid tumors.
Sutro Biopharma Appoints Clinical Development VP contractpharma
May 26, 2020
Dr. Craig Berman has more than 17 years of experience in drug development, including immuno-oncology.
Sutro Biopharma nets $85.4M to drive antibody-drug conjugates fiercebiotech
July 30, 2018
Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).
Celgene opts not to acquire Sutro Biopharma for $1bn, reworks existing partnership pharmafile
August 14, 2017
Celgene has announced that it has chosen not to scoop up Sutro Biopharma, rejecting to take advantage of an option outlined in its $1 billion partnership struck in 2014 which would allow it to acquire the US biotech.